105
Participants
Start Date
January 31, 2011
Primary Completion Date
October 31, 2012
Study Completion Date
October 31, 2012
Tivozanib
Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
Coastal Bend Cancer Center, Corpus Christi
Texas Oncology-Baylor, Charles A. Sammons Cancer Center, Dallas
BC Cancer Agency Vancouver Centre, Vancouver
Juravinski Cancer Center, Hamilton
Princess Margaret Hospital, Toronto
Sunnybrook Odette Cancer Center, Toronto, Toronto
Montreal General Hospital, Montreal
Southern Cancer Center, Mobile
Providence Health and Services, Burbank
David Geffen School of Medicine at UCLA, Los Angeles
Rocky Mountain Cancer Center, Denver
St. Francis Cancer Research Foundation, Beech Grove
Cancer Center of Kansas, Wichita
Medical Oncology, LLC, Baton Rouge
Dana Farber Cancer Institute, Boston
Cancer & Hematology Centers of Western Michigan, Grand Rapids
North Mississippi Hematology & Oncology Associates, Ltd., Tupelo
Comprehensive Cancer Centers of Nevada & US Oncology Research, Las Vegas
Mary Hitchcock Memorial Hospital, NH, Lebanon
University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill
Ohio State University, Columbus
Fox Chase Cancer Center, Philadelphia
The Jones Clinic, Germantown
The West Clinic, Memphis
Texas Oncology-Austin North, Austin
Lead Sponsor
AVEO Pharmaceuticals, Inc.
INDUSTRY